semaglutide type 1 diabetes automated insulin delivery randomized trial 2025 How Innovation is Transforming Type 1 Automated Insulin Delivery in Older

For patients first prescribed an AOM in December 2024, 50.5% filled a GLP-1 RA within 60 days

Gallagher T

Health Implications The decision to include Semaglutide under HSA and FSA points to a broader understanding of the essential role of weight management in maintaining overall health and reducing obesity around America

In a comprehensive systematic review published in 2014, Lynch and Adams demonstrated that fasting circulating BCAA concentrations were universally elevated in obese populationsreflecting impaired catabolic disposal rather than excess dietary intakeand positively correlated with the future risk of developing type 2 diabetes (T2D) (14)

doi: 10.1038/s41374-022-00732-8 84